Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Primary Purpose
Cystoid Macular Edema
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Standard Care
nepafenac
Sponsored by
About this trial
This is an interventional prevention trial for Cystoid Macular Edema focused on measuring cystoid macular edema, cataract, nonsteroidal antiinflammatory drugs, optical coherence tomography
Eligibility Criteria
Inclusion Criteria:
- over age 50
- having cataract surgery at UNC
Exclusion Criteria:
- medically controlled diabetes
- history of intraocular surgery
- abnormal pre-op optical coherence tomography scan
- history of ocular inflammation
- have age related macular degeneration
Sites / Locations
- University of North Carolina at Chapel Hill
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard Treatment
Nepafenac
Arm Description
topical antibiotic for 10 days and a topical corticosteroid for 1 month
1 drop per study eye three times per day for 30 days in addition to standard care
Outcomes
Primary Outcome Measures
Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups)
The endpoints of the study were change in macular thickness measured by OCT in the central 1mm diameter centred on the fovea (central macular thickness)
Pre-operative Best Corrected Visual Acuity (BCVA)
Patients were instructed to read letters on the EDTRS visual acuity chart. The mean and standard deviation for each group was measured. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.
Foveal Thickness
difference in mean pre-post changes by the two treatment groups
Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups)
Post-operative Best Corrected Visual Acuity (BCVA)
The patients were again instructed to read letters on the ETDRS chart 8 weeks post-surgery. The mean and standard deviation for each group was recorded. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.
Secondary Outcome Measures
Full Information
NCT ID
NCT00494494
First Posted
June 28, 2007
Last Updated
June 13, 2011
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Research to Prevent Blindness
1. Study Identification
Unique Protocol Identification Number
NCT00494494
Brief Title
Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Official Title
Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
Research to Prevent Blindness
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Purpose: Study the effect of nepafenac ophthalmic suspension 0.1% to prevent post-operative cystoid macular edema following uncomplicated cataract surgery
Participants: Patients having cataract surgery at UNC who meet eligibility criteria
Procedures (methods): Patients will have pre and post-operative vision measured and optical coherence tomography (OCT) testing, also cataract density and intraoperative phacoemulsification parameters including ultrasound power and ultrasound time will be measured. Patients will be randomized into two groups. Group 1 will be treated with standard post-operative cataract management. Group 2 will be treated with standard post-operative cataract management plus topical nepafenac for one month. Post-operative macular thickness will be studied by analyzing the visual acuity and OCT measurements at two months post surgery.
Detailed Description
We plan to enroll 80 patients in this prospective randomized clinical trial. Eligible patients will be randomized into two groups. All patients will have pre-operative Early Treatment of Diabetic Retinopathy Study (ETDRS) vision measured and pre-operative OCT (Humphrey-Zeiss Medical Systems, San Leandro, CA) in both eyes. OCT measurements will include total macular volume, central foveal thickness, and average macular thickness. Pre-operatively, all cataracts will be graded using the LOCS III classification system.10 Group 1 will receive pre-operative topical nepafenac to maintain intra-operative pupillary dilation which is standard care for cataract surgery. Following surgery Group 1 will be treated with standard post operative cataract treatment, including a topical antibiotic and a topical corticosteroid. Group 2 will also receive pre-operative topical nepafenac to maintain intra-operative pupillary dilation. Following surgery patients in Group 2 will be treated with topical nepafenac, a topical antibiotic, and a topical corticosteroid. Group 2 will be given the 3ml bottle of nepafenac to take home and instructed to use it three times per day for one month. Intra-operative surgical parameters including ultrasound time and average percent phacoemulsification power will be recorded for all surgeries. All patients will be seen on post-operative day one, one week, one month, and two months. At the two month visit, best corrected ETDRS vision and OCT will be repeated in both eyes. The two month visual acuity and post-operative OCT will be analyzed to evaluate the effect of nepafenac on CME following cataract surgery. Wilcoxon signed rank test will be used to compare pre-operative and post-operative differences between visual acuity and OCT measurements. The Spearman correlation will be used to compare the variables in the study including cataract density, ultrasound time, average percent phacoemulsification power, and OCT measurements.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystoid Macular Edema
Keywords
cystoid macular edema, cataract, nonsteroidal antiinflammatory drugs, optical coherence tomography
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
82 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard Treatment
Arm Type
Active Comparator
Arm Description
topical antibiotic for 10 days and a topical corticosteroid for 1 month
Arm Title
Nepafenac
Arm Type
Experimental
Arm Description
1 drop per study eye three times per day for 30 days in addition to standard care
Intervention Type
Drug
Intervention Name(s)
Standard Care
Intervention Description
topical antibiotic for 10 days plus topical corticosteroids for 1 month
Intervention Type
Drug
Intervention Name(s)
nepafenac
Intervention Description
liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
Primary Outcome Measure Information:
Title
Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups)
Description
The endpoints of the study were change in macular thickness measured by OCT in the central 1mm diameter centred on the fovea (central macular thickness)
Time Frame
baseline and 8 weeks
Title
Pre-operative Best Corrected Visual Acuity (BCVA)
Description
Patients were instructed to read letters on the EDTRS visual acuity chart. The mean and standard deviation for each group was measured. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.
Time Frame
baseline
Title
Foveal Thickness
Description
difference in mean pre-post changes by the two treatment groups
Time Frame
baseline and 8 weeks
Title
Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups)
Time Frame
baseline and 8 weeks
Title
Post-operative Best Corrected Visual Acuity (BCVA)
Description
The patients were again instructed to read letters on the ETDRS chart 8 weeks post-surgery. The mean and standard deviation for each group was recorded. Letters range from 0 (20/2000) to 110 (20/12.5), with the higher number signaling better visual acuity.
Time Frame
baseline and 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
over age 50
having cataract surgery at UNC
Exclusion Criteria:
medically controlled diabetes
history of intraocular surgery
abnormal pre-op optical coherence tomography scan
history of ocular inflammation
have age related macular degeneration
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth C Cohen, MD
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of North Carolina at Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27517
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
We'll reach out to this number within 24 hrs